LONDON, July 29 (Reuters) – AstraZeneca (AZN.L) is exploring options for the future of its COVID-19 vaccine and expects greater clarity on the matter by the end of 2021, a senior executive told Reuters on Thursday.
The review of the future of the vaccine comes after a series of setbacks in its race to produce a shot for the world. Executives emphasised it was too early to say what the decision on the vaccine’s future would be.
AstraZeneca agreed to work with the University of Oxford on its COVID-19 shot last year despite having no prior vaccine experience, taking on the project with a pledge not to make a profit during the coronavirus pandemic.
While a $39 billion dollar deal to buy rare drug firm Alexion is much more…

